NCT06913725View on ClinicalTrials.gov

An Exploratory Study to Evaluate the Efficacy and Safety of FCN-159 in Patients With Brain Arteriovenous Malformations

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2026

Conditions
Brain Arteriovenous Malformations
Interventions
DRUG

FCN-159

An investigational oral MEK inhibitor

Trial Locations (1)

No. 45, Changchun Street

RECRUITING

the Department of Neurosurgery, China International Neuroscience Institute, Xuanwu Hospital, Capital Medical University, Beijing

All Listed Sponsors
collaborator

Shanghai Fosun Pharmaceutical Industry Development Co., Ltd

UNKNOWN

lead

Xuanwu Hospital, Beijing

OTHER